Genoway Stock

Genoway EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Genoway (ALGEN.PA) as of Aug 3, 2026 is 45.35. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 16.75 — a change of 170.71% (higher).

EV/EBIT

45.35

YoY

170.71%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Genoway is 2026 45.35 . EV/EBIT (Enterprise Value to EBIT) of Genoway was 2025 16.75 . It decreases by 170.71% higher compared to the previous year.

The Genoway EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-6.47 base
Jan 1, 2020
-5.32 base
Jan 1, 2021
-8.24 base
Jan 1, 2022
37.14 base
Jan 1, 2023
19.69 base
Jan 1, 2024
20.38 base
Jan 1, 2025
50.43 base
Jan 1, 2026 (e)
73.77 base
YEARPRICE-TO-EBIT
2026 est 73.77
2025 50.43
2024 20.38
2023 19.69
2022 37.14
2021 -8.24
2020 -5.32
2019 -6.47
2018 14.33
2017 9.97
2016 9.92
2015 18.08
2014 30.44
2013 35.07
2012 -15.14
2011 24.77
2010 14.77
2009 29.61
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

Genoway Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Genoway's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Genoway's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Genoway's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Genoway grows earnings faster than its peers.

Genoway Stock analysis

What does Genoway do? Genoway SA is a biotechnology company based in Lyon, France. It was founded in 2002 by Pierre Cadinot. The company specializes in the production of genetically modified mice for disease research and the development of new therapies. The business model of Genoway is to provide customers with customized genetically modified mice. The company offers a wide range of services, from consulting during the design phase to the delivery of modified mice. The company also offers services in the field of cell culture and transgene expression. Genoway is divided into different divisions to meet specific customer needs. For example, there is the "Knockout Mice" division, which specializes in producing mice that lack a specific target gene. These mice are used to study the function of the missing gene in vivo. Another area of Genoway is the production of "humanized mouse models". These are mice in which human genes have been inserted to model specific human diseases or to test the efficacy of drugs. These humanized mice are an important part of drug research in the pharmaceutical industry. Genoway also offers services in the field of inducible expression. This involves triggering the expression of a target gene in vivo to study the effects of the protein. This technology is particularly useful in the research of diseases such as cancer, where certain genes are only active in specific cells. In addition to these specialized services, Genoway also offers a wide range of standard services, such as the creation of stable cell lines or transgene expression in various organs and tissues. Genoway is a leading company in the development of genetically modified models for the study of human diseases. The company works closely with its customers to develop customized solutions that meet the specific requirements of each project. With its divisions and services, it aims to support its customers in the development of new therapies and drugs. Genoway is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genoway stock

EV/EBIT (Enterprise Value to EBIT) of Genoway is 45.35 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Genoway changed from 16.75 to 45.35, representing a 170.71% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Genoway since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Genoway with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Genoway

All Key Metrics — Genoway